Progress on Development of RNA Base Editing Technologies for Precision Medicines, including Axiomer® platform presented at TIDES EU by Gerard Platenburg - ProQR Therapeutics
ProQR will focus exclusively on the development of the Axiomer® RNA editing technology platform across multiple therapeutic areas. This comes following feedback from the European Medicines Agency (EMA) related to ProQR’s sepofarsen for Leber Congenital Amaurosis type 10 (LCA10).
… focuses on developing potential medicines using our Axiomer ® RNA editing platform technology. Strategic … drive the advancement of an early-stage technology, like Axiomer , closer to the clinic. In any global licensing and … of high unmet need Lenka van Sint Fiet, Director AxiomerAxiomer technology ProQR’s Axiomer ® platform …
… ADAR endogenous machinery This presentation reviews Axiomer editing oligonucleotides (EONs) structure activity, the potential of Axiomer platform as well as its applicability for the … on June 1, 2023 by Monica Aguila - ProQR Therapeutics Axiomer platform uses editing oligonucleotides (EONs) to …
… Oligonucleotides to Address Liver Originated Disorders Axiomer platform presentation highlighting the potential of … and is currently in charge of our Innovation unit. Axiomer ® , an RNA editing platform, uses chemically modified … and the presentation will review the potential of Axiomer platform in multiple organs as well as its …
… presentation highlights the therapeutic possibilities of Axiomer platform that are not limited to disease causing … and is currently in charge of our Innovation unit. Axiomer ® , an RNA editing technology, uses Editing …
